热门资讯> 正文

Phathom表示FDA确认Voqueza独家经营权至2032年5月

2025-06-16 21:13

Phathom Pharmaceuticals (NASDAQ:PHAT) said that the U.S. FDA has updated its "Orange Book" to reflect that Voquezna (vonoprazan) new chemical entity exclusivity is valid through May 3, 2032.
The exclusivity applies to both the 10 mg and 20 mg tablets.
Earlier this month, the FDA granted Phathom's Citizen Petition requesting the change.

More on Phathom Pharmaceuticals

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long
Phathom Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation
Phathom surges 125% after FDA grants petition on Voquezna exclusivity
Phathom Pharmaceuticals surges 50% following large insider purchase

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。